News Eisai: UK gives pharma a poor deal, may invest elsewhere Japanese pharma getting frustrated with NICE
Views & Analysis Accessing biosimilars: untapped potential in EU and US Though they can reduce the costs of health care, biosimilars still face challenges to access.
News NICE rejects Eisai's Halaven in new breast cancer use NICE rejects drug after finding gap in clinical data
Views & Analysis Medical affairs: leading a transformation in medicines Medical Affairs is leading the change towards a more patient and customer-centric, data driven industry.
Views & Analysis Bureaucracy and duplication: the reality of the PPRS Has the PPRS delivered on the aim of reducing bureaucracy and duplication?
News NICE backs funding for Pfizer, Novartis breast cancer drugs Pfizer had been giving drug free to NHS before decision
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
